Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2565 of 7686 results

  1. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]

    Awaiting development [GID-TA11625] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure

    In development [GID-NG10405] Expected publication date: TBC

    NICE guideline
    In development

  3. Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452

    In development [GID-TA11557] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years ID6484

    Awaiting development [GID-TA11610] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment

    In development [GID-HTE10056] Expected publication date: 24 April 2025

    Health technology evaluations
    In development

  6. Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]

    In development [GID-TA11587] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  7. Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]

    In development [GID-TA11452] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  8. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development [GID-TA11386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. LY3209590 for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]

    Awaiting development [GID-TA11645] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. LY3209590 for treating type 2 diabetes in people on daily insulin injections [ID6499]

    Awaiting development [GID-TA11644] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Digital platforms for community based self-management of mild to moderate osteoarthritis and joint pain: Early value assessment

    Awaiting development [GID-HTE10057] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  12. Kidney Cancer

    In development [GID-NG10398] Expected publication date: TBC

    NICE guideline
    In development

  13. Zuranolone for treating severe postnatal depression ID6431

    In development [GID-TA11356] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Tobacco: preventing uptake, promoting quitting and treating dependence - Cytisine for smoking cessation

    In development [GID-NG10427] Expected publication date: 04 February 2025

    NICE guideline
    In development

  15. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]

    In development [GID-TA10877] Expected publication date: 08 January 2025

    Technology appraisal guidance
    In development